CEO of Alligator Bioscience on the company's BD strategies in immuno-oncology

Per Norlen, CEO of Alligator Bioscience, tells Scrip's Jo Shorthouse about the recent addition to the pipeline, and the next big milestones for the company, which develops immuno-oncology antibodies. Three years after a global licensing deal with Janssen, he shares his thoughts on the present landscape for partnering in IO therapies.